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ER stress(TUDCA) is a unique natural compound that acts as a potent anti-apoptotic and
anti-oxidant agent, reducing cytotoxicity in several neurodegenerative diseases. Since oxidative stress,
apoptosis and inﬂammation are associated with transthyretin (TTR) deposition in Familial Amyloidotic
Polyneuropathy (FAP), we investigated the possible TUDCA therapeutical application in this disease. We
show by semi-quantitative immunohistochemistry and western blotting that administration of TUDCA to a
transgenic mouse model of FAP decreased apoptotic and oxidative biomarkers usually associated with TTR
deposition, namely the ER stress markers BiP and eIF2α, the Fas death receptor and oxidation products such
as 3-nitrotyrosine. Most important, TUDCA treatment signiﬁcantly reduced TTR toxic aggregates in as much
as 75%. Since TUDCA has no effect on TTR aggregation “in vitro”, this ﬁnding points for the “in vivo”
modulation of TTR aggregation by cellular responses, such as by oxidative stress, ER stress and apoptosis and
prompts for the use of this safe drug in prophylactic and therapeutic measures in FAP.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionTauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid
normally produced endogenously in humans at very low concentra-
tions. TUDCA is formed in the conjugation pathways of ursodeoxy-
cholic acid (UDCA), which is commonly used in bile acid replacement
therapy for the treatment of certain cholestatic syndromes. Recent
reports have shown that both hydrophilic bile acids, UDCA and
TUDCA, can prevent hepatic cytotoxicity through several mechanisms.
For example, TUDCA prevents the production of reactive oxygen
species (ROS) and thus acts as an anti-oxidant [1]. Additionally, TUDCA
mitigates mitochondrial insufﬁciency and toxicity preventing apop-
tosis, namely by inhibiting Bax translocation from the cytosol to
mitochondria. In hepatocytes, this inhibition results in reduced
mitochondrial membrane perturbation, release of cytochrome c and
activation of downstream caspases [1–4]. Moreover TUDCA proved to
be neuroprotective in a genetic mouse model of Huntington's disease
(HD). Drug treatment leads to marked reduction in striatal cell apop-
tosis and degeneration, and in intracellular inclusions typical of HD
[5]. The neuroprotective effect of this drug was also conﬁrmed in rat
models of Parkinson disease (PD) [6], ischemic and hemorrhagic
stroke [7,8].tituto de Biologia Molecular e
el.: +351226074900; fax: +351
l rights reserved.Familial Amyloidotic Polyneuropathy (FAP) is an autosomal do-
minant hereditary disease characterized by the extracellular deposi-
tion of amyloid ﬁbrils in the connective tissue, affecting particularly
the peripheral nervous system [9]. Amyloid ﬁbrils are composed of
mutant transthyretin (TTR), a homotetrameric protein that transports
thyroxine (T4) in the plasma [10]. Research on the dynamics of TTR
aggregation into amyloid ﬁbrils, characterized different molecular
species suggesting a model involving several steps, namely dissocia-
tion of the tetramer and polymerization of the resulting monomers
into non-ﬁbrillar oligomers, leading to protoﬁbrils that elongate
further into mature ﬁbrils [11]. According to this proposed mechan-
ism, stabilization of the tetramer would be a fundamental step for the
inhibition of amyloid ﬁbril formation.
Cytotoxicity caused by the aggregation and tissue deposition of TTR
Val30Met has been described in FAP. Oxidative stress, inﬂammation
and activation of caspase-3 were detected in a pre-symptomatic stage
of the disease when aggregation of non-ﬁbrillar TTR is detected [12].
Increased levels of oxidative metabolites, including hydroxynone-
nal (HNE) and 8-hidroxy-2′-deoxiguanosine (8-OHdG) are found in
tissues presenting TTR aggregation not only in transgenic animals but
also in human FAP biopsies [13]; furthermore, Fas and caspase-8
activation are observed in tissues with TTR deposition, suggestive of
activation of death receptor pathways not involving the mitochondria
[13]. Recent data from our group showed activation of the classical
Unfolded-Protein Response (UPR) pathways in tissues not specialized
in TTR synthesis but presenting extracellular TTR aggregates [14].
Transgenic mice for human TTR Val30Met mutation, in a null
background serve as an animal model for TTR deposition and cons-
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therapeutic strategies. This animal model for TTR amyloidosis shows
deposition of non-ﬁbrillar mutant TTR starting at 3months of age; TTR
amyloid ﬁbrils are detected at 9 months of age, with particular in-
volvement of the gastrointestinal tract [15,16].
Thus, we reasoned that sub-chronic administration of TUDCA in
this animal model could exert effect on apoptotic pathways and oxi-
dative environment normally associated with FAP. We herein report
the “in vivo” effect of TUDCA, a well characterized and widely used
drug in the FAP animal model.
2. Materials and methods
2.1. Transgenic mice
3 month old transgenic mice bearing the human TTR Val30Met
mutation, in a TTR null background-hTTRMet30 (n=15) were used for
the experiment [15]. Animals were kept and used strictly in
accordance with National and European Union Guidelines for the
care and handling of laboratory animals. Animals were treated with
TUDCA (Calbiochem, San Diego, CA, USA), at a concentration of
500 mg/kg/day in the drinking water, during a 3 month period. An
age-matched control group of animals was maintained in the same
conditions, drinking regular tap water. After 3 month treatment,
animals were sacriﬁced after anesthesia with ketamine/xylazine. All
mice's tissues, including esophagus, stomach, small and large
intestines were immediately excised and frozen at −70 °C or ﬁxed in
4% neutral buffered formalin and embedded in parafﬁn for light
microscopy techniques.
2.2. Immunohistochemistry
5 µm-thick sections were deparafﬁnated in histoclear (National
Diagnostics, Atlanta, Georgia, USA) and dehydrated in a descent
alcohol series. Endogenous peroxidase activity was inhibited with 3%
hydrogen peroxide/100%methanol and sections were blocked with 4%
fetal bovine serum and 1% bovine serum albumin in PBS. Primary
antibodies used were: rabbit polyclonal anti-Fas (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA, 1:100), rabbit polyclonal anti-3-nitrotyr-
osine (Chemicon International, Temecula, CA, USA, 1:500), goat
polyclonal anti-BiP (Santa Cruz Biotechnology, Santa Cruz, CA, USA,
1:50) and ﬁnally, rabbit polyclonal anti-TTR (Dako, Carpinteria, CA,
USA, 1:1000), which were diluted in blocking solution and incubated
overnight at 4 °C. Antigenvisualizationwas performedwith the biotin-
extravidin-peroxidase kit (Sigma-Aldrich, St. Louis, MO, USA), using 3-
amino-9-ethyl carbazole (Sigma-Aldrich, St. Louis, MO, USA), or
diaminobenzidine as substrates. On parallel control sections, the
primary antibodywas replaced by blocking buffer and by non-immune
immunoglobulins corresponding to the species used for primary
antibodies, namely rabbit and goat; staining was absent under these
conditions.
Semi-quantitative immunohistochemistry (SQ-IHC) analysis was
performed using Scion Image software. This application enables the
measurement of the area occupied by pixels corresponding to the
immunohistochemical substrate's color that is normalized relatively
to the total area. Each slide was analysed in 5 different representative
areas. Results shown represent % occupied area (±SD).
2.3. Total protein extracts
Mice stomach (approximately 5 mg) was homogenized on ice in a
small glass rod homogenizer in 1 mL of lysis buffer that contained
EDTA, EGTA, MOPS, Triton, PMSF and proteases inhibitors (Amersham
Biosciences, NJ, USA). Total homogenates were centrifuged at
14,000 rpm for 30 min. Supernatants were separated and proteins
quantiﬁed by the Bradford protein assay (BioRad, CA, USA).2.4. Western blot
Equal amounts of protein from mice stomach lysates were
separated in a 15% SDS-PAGE and transferred onto a nitrocellulose
Hybond-C membrane (Amersham) in a semi-dry system. The primary
antibodies used were: goat polyclonal anti-BiP (Abcam, Cambridge,
UK, 1:1000), rabbit polyclonal anti-eIF2α [P] (Biosource, CA, USA,
1:500) and mouse monoclonal anti-β-actin (Sigma, MO, US, 1:5000).
The enhanced chemiluminescence method ECL-plus (Amersham
Biosciences, NJ, USA) was used to develop the blots. Quantitative
analyses of western blots images were performed using the Scion
software (Scion Corporation) and results are represented as the
average of the mice representative of a group (treated versus non-
treated).
2.5. Study of TTR aggregation by TEM (transmission electron microscopy)
TEM analysis was used to follow TTR aggregation, as previously
described [17].Soluble TTR Tyr78Phe (substitution of a tyrosine for a
phenylalanine at position 78) at 2 mg/mL was dialysed against PBS
and incubated at 37 °C in the absence or presence of TUDCA at a molar
ratio of 1:100. The protein concentration was determined by the
Lowry method [18]. After 48 h of incubation, samples were analysed
by TEM.
For visualization by TEM, sample aliquots were diluted (1:50) in
PBS and negatively stained with 1% uranyl acetate. The grids were
visualized with a Zeiss microscope (model EM10C), operated at 60 kV.
2.6. TTR tetrameric stability assays by isoelectric focusing (IEF) under
semi-denaturing conditions
30 µl ofmice plasmawas subjected to native PAGE and the gel band
containing TTR was excised and applied to an IEF gel. IEF was carried
out in a polyacrylamide gel containing 5% ampholytes pH 4–6.5 and in
the presence of 4 M urea, at 1200 V for 6 h, essentially as previously
described [17]. These semi-denaturing conditions allow the visualiza-
tion of bands corresponding to TTR monomers and tetramers (which
include hybrid species composed of reduced and oxidized TTR
monomers), and also of an oxidized form of the monomer. Proteins
were ﬁxed with 20% (v/v) of trichloroacetic acid and stained with
Coomassie Blue, and the dried gel was scanned (hp Scanjet G3010;
Hewlett Packard) and subjected to densitometry (program Image
Quant, version 5.1, Molecular Dynamics). Four samples of each treated
and untreated (control) serum samples were analysed and the
tetramer/monomer ratios were evaluated. The results were expressed
as the mean and standard deviation of the ratios.
2.7. TTR quantiﬁcation
TTR was quantiﬁed by radial immunodiffusion (RID) using the
Human Prealbumin Bindarid – Radial Immunodiffusion Kit (The
Binding Site, Birmingham, UK).
2.8. Statistical analyses
All data examined were expressed as mean±S.D. Comparison
between groups was made using the Student's t test. A P value of less
than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. TUDCA has no effect on TTR aggregation and stabilization
We ﬁrst investigated the effect of TUDCA on TTR ﬁbril formation,
namely on the aggregation of Tyr78Phe TTR. This variant is very prone
to ﬁbril formation [17]. Incubation of TUDCA with soluble TTR
Fig. 1. (A) Aggregation of TTR Tyr78Phe observed by TEM. The initial preparation (0 h)
contains round particles resembling TTR Tyr78Phe. After 48 h at 37 °C, the protein
aggregates and forms oligomers of different sizes. Incubation with TUDCA for 48 h
does not prevent aggregation, and large aggregates are clearly visible. 20× magniﬁca-
tion; (B) Analysis of mice plasma TTR by IEF. The different visualized molecular species
are indicated. Note the stronger bands corresponding to tetramers and the absence of
the monomer band in samples treated with iododiﬂunisal (reference for the
stabilization effect); TUDCA treated mice parallels the result of control mice. IDIF,
iododiﬂunisal. (⁎ Pb.05).
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guishable from the control without drug (Fig. 1A). When the period of
incubation was increased to 15 days, ﬁbril formation could be visu-
alized, indicating that TUDCA neither inhibits TTR aggregation nor has
ﬁbril disruption activity (data not shown).
The effect of TUDCA on TTR tetramer stabilizationwas investigated by
IEF in the presence of 4M urea. Plasma samples from treated hTTRMet30
and control untreatedmicewere compared concerning bandpatterns andtetramer/monomer ratios. In parallel, plasma from control mice was
incubated with iododiﬂunisal (dissolved in DMSO) as a reference for the
stabilization effect [17]. Under the used conditions, TTR presented a
characteristicpatternof twomainbands, representingmonomers (normal
and oxidized form) and several bands of lower pI, representing different
forms of the tetramer [19]. Mice receiving TUDCA at a concentration of
500mg/kg/day did not showTTR tetrameric stabilizationwhen compared
to control animals (Fig. 1B); thus, the proportion of tetramer to monomer
was foundtobe0.51 inTUDCAtreatedmice, as compared to0.54 incontrol
samples, as determined by densitometric analyses.
TTR was quantiﬁed using radial immunodiffusion with anti-TTR
antibody. Randomplasmasamples frommice treatedwithTUDCA (n=5)
and controls (n=5)were compared and the results were 275.5±151.1 µg
TTR/mL and 386.6±216.1 µg TTR/mL respectively, which do not differ
signiﬁcantly.
3.2. TUDCA decreases TTR deposition in the gastrointestinal tract of hTTR
Met30 transgenic animals
The anti-apoptotic drug TUDCA was given at a concentration of
500 mg/kg/day to hTTR Met30 mice. This dose was previously used
[20] in rats and produced no adverse effect. The treatment was
performed during 3months and started whenmicewere 3month old,
before they present TTR deposition in the gastrointestinal tract, the
major target organ in this animal model. Mice seems to tolerate well
the 500 mg/kg/day dose, since they do not exhibit any sign of disease
and the weight gain was similar to control animals (data not shown).
We analysed the effect on TTR deposition by performing TTR
immunohistochemistry (IHC) in different organs. Non-treated animals
presented widespread TTR staining, as expected, in the gastrointest-
inal tract. In the group of TUDCA treated mice, we detected reduction
of approximately 75% on TTR deposits in the stomach as can be seen in
the representative IHC images and respective quantiﬁcation of Fig. 2A.
A similar decrease in TTR staining was detected in the esophagus and
large bowel (colon) (Fig. 2A).
These results sustained that TUDCA acts as a potent blocker of TTR
deposition.
3.3. Oxidation is signiﬁcantly decreased by TUDCA “in vivo”
Weassessed 3-nitrotyrosine (3-NT) levels in TUDCA treatedmice as
a protein marker of oxidative stress. 3-NT is described as being
increased not only in axons of FAP patients but also in tissues from
transgenic mice [12,16]. 3-NT immunohistochemistry was performed
in the gastrointestinal tract of TUDCA treated animals and age-
matched controls; approximately two fold decrease in the NT levels in
the esophagus and stomach of drug treated mice was observed; to a
lesser extent, 3-NT was decreased in the colon as well (Fig. 2C).
3.4. TUDCA decreased ER stress and apoptosis “in vivo”
The engagement of death receptors on the cell surface was
addressed as a possible apoptotic pathway involved in FAP. Ligand-
induced aggregation of members of the tumor necrosis factor (TNF)
receptor family, such as Fas (CD95) attracts FADD, which recruits
procaspase-8 molecules. The autocatalytic activation of caspase 8 by
Fas receptor can directly trigger the effector caspase 3 or, trough BiD,
interfere with Bcl-2 family members [21,22]. Thus, we proposed to
analyse by IHC the Fas receptor inTUDCA treatedmice and controls.We
observed that treatedmice presented decreased levels of Fas along the
gastrointestinal tract, as can be seen by representative pictures of the
esophagus, stomach and larger bowel (colon) of hTTRMet30mice that
were given TUDCA (Fig. 2B); control animals presented the expected
TTR deposition for 6 month old hTTR Met30 mice.
Since the ER is receiving increased attention as an important
compartment participating in stress induced apoptosis, activation of
Fig. 2. Representative immunohistochemistry of TTR (A), Fas (B) and 3-NT (C) in esophagus, stomach and colon of TUDCA treated mice (lower panel; n=15) and age-matched controls
(upper panel; n=10). 20× magniﬁcation; quantiﬁcation of immunohistochemical images of TTR, Fas, and 3-NT staining is represented as percentage of occupied area±SD (⁎ Pb.05,
⁎⁎Pb.01, #Pb.005).
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chaperone BiP. The involvement of ER stress as a target for TUDCA
action was conﬁrmed by a decrease of approximately 70% of the ER
chaperone BiP, in the esophagus and colon of TUDCA treatedmice (Fig.
3A), and a less pronounced decrease of 35% in the stomach. The
staining was observed particularly at the mucosa level. To conﬁrm the
IHC results for ER stress in the gastrointestinal tract, we quantiﬁed BiP
and eIF2α [P] in stomach lysates of control (n=5) and TUDCA treated
mice (n=6). The levels of ER chaperones were lower in mice that
received the drug, suggesting TUDCA action at ER stress level (Fig. 3B).
4. Discussion
In this study we showed that administration of TUDCA, a non-toxic
hydrophilic bile acid to a transgenic mouse model of FAP, signiﬁcantlyreduced TTR toxic aggregates and decreased apoptotic and oxidative
biomarkers usually associated with TTR deposition.
The interest of this application arose from the knowledge that
apoptotic and oxidant conditions can cause aggregation of amyloi-
dogenic Aβ peptide [23] and tau [24] and that in AD a complex
crosstalk is observed between calcium desregulation, reactive
oxygen species (ROS) and protein aggregation [25–27]; since these
events are also associated with TTR aggregation in FAP [13,14], we
proposed to investigate the effect of sub-chronic administration of
TUDCA to hTTR Met30 mice starting at 3 months of age, in the
beginning of TTR deposition. After 3 month treatment we observed
that while non-treated animals presented widespread TTR staining,
particularly in the gastrointestinal tract, TUDCA treated mice group
had approximately 75% reduction in TTR deposition in the same
organs.
Fig. 3. (A) Representative immunohistochemistry of BiP in esophagus, stomach and colon of TUDCA treatedmice (lower panel; n=15) and age-matched controls (upper panel; n=10).
20× magniﬁcation; quantiﬁcation of immunohistochemical images is represented as percentage of occupied area±SD (⁎Pb.05, #Pb.005). (B) Representative anti-BiP and anti-eIF2α
[P] western blots of stomachs from TUDCA treated and non-treated mice. Histogram: normalized BiP/β-actin and eIF2α [P]/β-actin density quantiﬁcations±SD (⁎Pb.05). TUDCA
treated mice (n=6) parallel the result of control mice (n=5).
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representative of FAP apoptosis were affected by TUDCA administra-
tion [13]. Contrary to work published in the literature on primary
human and mouse hepatocytes reporting Fas receptor expression as
not signiﬁcantly affected by TUDCA [4,28], we observed “in vivo”
decreased levels of Fas in the gastrointestinal tract in hTTR Met30
treated mice. Ramalho et al. [29] described that TUDCA reduced
caspase 2 and 6 activation, but not caspase 8,modulating Bcl-2 and Bax
levels. Based on our data, we consider that under the used conditions
and in this particularlymousemodel, TUDCA effect was not dependent
on mitochondrial pathways. The anti-apoptotic protein Bcl-2 was
unaffected after 3month treatment (data not shown). In the sameway,
Bax did not present any difference between treated and control
animals (data not shown). The differences found between the other
models described in the literature and FAP could be due to the fact that
TTR deposition is extracellular, in opposition to other neurodegenera-
tive diseases with intracellular aggregation.
Recent studies challenge the central role of mitochondria in apop-
tosis and suggest that some apoptotic signals, namely those occurring
in the ER, may bypass mitochondria to directly activate caspases
[30,31]. Xie et al. described that TUDCA abolishes ER stress by re-
ducing calcium efﬂux, BiP induction and caspase 12 activation [32].
The signiﬁcative decrease of the ER stress markers BiP and iE2 in
the GI tract of the animals in the present report is highly likely to be
related to the well known properties of TUDCA on ER stress; recent
data demonstrated clearly activation of the classical UPR pathways in
FAP tissues not specialized in TTR synthesis but presenting extra-
cellular TTR aggregate and ﬁbril deposition; cytotoxicity by Ca2+ efﬂux
from the ER in cell cultures incubated with TTR oligomers evidenced
ER stress associated with extracellular aggregates [14].
As a ﬁnal point, we investigated whether TUDCA could affect oxi-
dative stress on the tissues damaged by TTR deposition. In the group ofTUDCA treated mice, we observed a decrease in the well established
biomarker 3-NT for protein oxidative nitration in the gastrointestinal
tissues concordant with the decrease on TTR aggregation. This result
was in accordance with previous reports of TUDCA protection proper-
ties of rat liver proteins and lipids against oxidative damage [33].
Although the mechanism by which TUDCA decreases TTR deposi-
tion in transgenicmice remains to be elucidated, TUDCA effect as a TTR
stabilizer and inhibitor of ﬁbril formation was discarded; we believe
that TUDCA can act at multiple levels of apoptotic and oxidative
mechanisms early in the FAP pathology, and that oxidative stress and
apoptosis impact on extracellular TTR deposition. A possible mechan-
ism is the inﬂuence of secreted metabolites generated by oxidative
stress and apoptosis on TTR aggregation; for instance, in Alzheimer's
disease it was reported that abnormal oxidativemetabolites, including
hydroxynonenal (HNE) and cholesterol-derived aldehydes, modify Aβ
and accelerate the early stages of amyloidogenesis [34]. As ER stress
and oxidative stress are biomarkers associated with TTR deposition in
FAP patients and in asymptomatic carriers of Val30Met TTR, TUDCA
treatment in FAP might reduce apoptotic stress and consequently
lower extracellular TTR deposition and the toxic effects induced by
TTR aggregates, as our “in vivo” experiments suggest.
The only efﬁcient therapy available till now for FAP is liver trans-
plant. Liver transplant abolishes the synthesis of the variant TTR (at
least by the liver) avoiding further amyloid deposition and delaying the
progression of the disease. However, this is a very invasive therapy
with a high risk for the patients and limited availability of livers for
transplant [35]. Moreover, liver transplant does not prevent TTR syn-
thesis by the choroid plexus and the eye, the other major sites of TTR
synthesis. Furthermore, not all patients respond to this therapy. For
those reasons, therapies based on the development and administration
of compounds inhibiting amyloid ﬁbril formation and the toxic affects
induced by TTR aggregates are ideal alternative strategies.
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rupting TTR amyloid ﬁbrils “in vivo” [36]; these descriptions lead to
ongoing clinical trials in FAP with doxycycline. To have a drug that
avoids polymerization “in vivo” such as TUDCA will certainly have
prophylactic value since cytotoxicity begins early before amyloid de-
position; a therapeutic value can also be considered for TUDCA admi-
nistration in FAP patients, after adaptation of TUDCA dosage and
regiments, namely if administered in conjunction with an amyloid
disrupter such as doxycycline.
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